Immune Checkpoint Inhibitor
Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis
... headache or visual changes. A random (1 pm) serum cortisol was drawn and was found to be 2.0 μg/dL (Fig. 2), with an ACTH of 16 pg/mL (ref: 7-69pg/mL). Further pituitary hormone evaluation was performed at 4 pm on the ...
5
The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis
... Abstract: The value of immune checkpoint inhibitor (ICI) combination therapy for patients with lung cancer remains unclear. We conducted a meta-analysis using PubMed, Embase, and ClinicalTrials.gov ...
15
Molecular imaging biomarkers for immune checkpoint inhibitor therapy
... ICI: immune checkpoint inhibitor; IHC: immunohistochemistry; IL2: interleukin-2; irAE: immune-related adverse event; LAG-3: lymphocyte activation gene 3; mAb: monoclonal antibody; MDSC: ...
11
<p>Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor</p>
... anti-cancer immune response is too weak to effectively clear cancer ...robust immune response to malignant cells is a hot research topic in cancer therapeutics fi ...especially immune ...
12
Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis
... Immune checkpoint inhibitor (ICI) therapy has revolution- ized cancer ...particularly immune-mediated diarrhea and/or colitis (IMDC), which is among the most common irAEs and frequently forces ...
11
Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies
... combination checkpoint inhibitor therapy (dosing regimen: ipilimumab 3 mg/kg three weekly, nivolumab 1 mg/kg three weekly) after two melanoma deposits had been resected from his ...combination immune ...
5
Search Terms: adverse events, immune checkpoint inhibitor, myasthenia gravis
... Diagnosing myasthenia gravis is often straightforward as symptoms are quite characteristic, including fluctuation of ocular or bulbar symptoms and/or weakness of neck and proximal limb muscles without sensory deficits ...
41
Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer
... The first two decades of the twenty-first Century have yielded truly substantive advances in our understand- ing of: a) the impact of driver mutations in individual patients’ cancers; and b) the dynamic relationship ...
6
Immune Checkpoint Inhibitor Related Neuropathic Adverse Effects on Cancer Patients
... application, immune checkpoint inhibitors (ICIs) intervention is being increasingly common for multiple ...as immune-related adverse effects (irAEs) ...of immune-modulating ...
12
Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
... However, although ICIs are a promising cancer therapy, they also come with challenges. ICIs cause a widespread activation of T-cells that is not tumor-specific [9]. This ac- tivation, coupled with the depletion of ...
11
Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab
... Diarrhea is a well-known side effect of ICPIs that often requires the use of steroids to induce remission. In steroid-refractory cases, biologic agents such as inflixi- mab have been increasingly employed with good ...
8
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
... with checkpoint inhibitors across these five institutions and identified 11 cases, several presumed to be ITP based on clinical diagnostic ...point inhibitor therapy were reviewed, suggesting an incidence ...
6
Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
... Nonetheless, ICI therapy has some drawbacks, in par- ticular, immune-related adverse events (irAEs). IrAEs can affect almost any organ system and range from mild self-limiting symptoms to severe life-threatening ...
12
Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
... Owing to the immunological mechanism of ICPIs, their adverse effects collectively fall under the umbrella of immune-related adverse events (irAEs). Although ICPI-induced irAEs can affect virtually any organ ...
11
Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment
... Background: Immune checkpoint inhibitors (ICIs) represent a promising novel class of cancer therapy, but immune- mediated adverse events can complicate ICI ...
8
Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature
... controlling immune dysregulation in these patients might be limited by the constant presence of the original trigger; the circulating ICIs, as their half- life ranges from ...
11
<p>Hyperprogressive Disease In Cervical Small Cell Carcinoma Treated By Immune Checkpoint Inhibitor</p>
... Therefore, the patient received six cycles of pembrolizu- mab, a PD-1 inhibitor, 150mg q3w, from November 2016 to March 2017. Meanwhile, monitoring of circulating tumor DNA (ctDNA) mutation abundance, detection of ...
5
Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report
... of immune-mediated encephal- itis remains ...of immune-mediated encephalitis ...developed immune-mediated encephalitis related to immune checkpoint inhibitor therapy ...of ...
8
Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: a case report
... Novel immune checkpoint inhibitors have been often utilized for different types of malignancies as salvage therapy with varying ...to immune checkpoint inhibitor use is the higher ...
6
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
... benefit, immune checkpoint inhibitor (ICI) therapy in particular has re- ceived considerable attention because these agents im- prove overall survival and are effective in a wide range of tumor types ...
23